Navigation Links
Vitamin D deficiency confirmed as common across a range of rheumatic conditions
Date:6/18/2010

Rome, Italy, Friday 18 June 2010: Two separate studies have shown that vitamin D deficiency is common in patients with a range of rheumatic diseases, with over half of all patients having below the 'normal' healthy levels of vitamin D (48-145 nmol/L) in their bodies. A further study assessing response to vitamin D supplementation found that taking the recommended daily dose did not normalise vitamin D levels in rheumatic disease patients. The results of these three studies were presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

A UK study1 of 180 patients aimed to assess mean levels of vitamin D in patients with inflammatory joint diseases, osteoarthritis and myalgia (muscle pain that, when experienced long term may be associated with nutritional deficiency). Data on vitamin D levels were gathered and results showed that 58% of individuals with a rheumatic condition had levels below that clinically considered to be 'sufficient' in healthy subjects (48-145 nmol/L).

An Italian study2 of 1,191 RA patients aimed to determine a correlation between vitamin D deficiency and several different clinical measures of disease activity. Researchers found that, regardless of supplementation, levels of 25-hydroxyvitamin D (25(OH)D), (a standard clinical measure of vitamin D in the blood), were lower than healthy levels (<50 nmol/L) in 85% of the patients not taking a vitamin D supplement and in 60% of those taking 800 IU or more vitamin D daily as a supplement. In non-supplemented patients levels of 25(OH)D significantly correlated with three measures of disease activity - the Health Assessment Questionnaire Disability Index, (p=0.000) the Mobility Activities of Daily Living Score (p=0.000) and the Number of Swollen Joints count (p=0.000).

"We have seen in studies that vitamin D deficiency is common in patients with a range of rheumatic diseases, and our results have confirmed this using several clinically accepted measures of disease activity," said Dr. L. Idolazzi, of the Rheumatology Unit, University of Verona, Italy. "What we need to see now is a range of long term studies, which examine the clinical response of patients to vitamin D supplementation."

Furthermore, a third study undertaken in Italy3 aimed to evaluate the affect of vitamin D supplementation in patients with inflammatory autoimmune disease (IAD) and non-inflammatory autoimmune disease (NIAD). Following supplementation, only 29% patients reached vitamin D levels greater than the level clinically considered to be 'sufficient' in healthy subjects, with no significant differences in vitamin D levels observed between the IAD and NIAD groups.

"Whilst it is well known that hypovitaminosis D is often seen in patients with inflammatory autoimmune diseases, the effects of supplementation have not been fully investigated in this setting," said Dr. Pier Paolo Sainaghi of the Immuno-Rheumatology Clinic, A. Avogadro University of Eastern Piedmont, Novara, Italy and author of the third study. "The results of our study show that daily 800-1,000 IU supplementation is not sufficient to normalise vitamin D levels in patients with rheumatologic or bone conditions. What is unclear is whether a higher dose would be more effective."

Study designs and key statistics

The UK study1 involved patients with a diagnosis of rheumatoid arthritis (RA), osteoporosis, or unexplained muscle pain, (total n=90, 30 from each group). These patients were matched with a control group of patients presenting with chronic back pain for a minimum of 6 months (n=90). The RA patient group registered median levels of vitamin D of 36 nmol/L (range 16-85 nmol/L, p=0.045) and in osteoporosis patients, these levels were slightly lower with a median value of 31 nmol/L (range 7-82 nmol/L, p=0.005). Patients with unexplained muscle pain had equally low median levels of vitamin D at 31 nmol/l (range 11-79 nmol/L, p= 0.008).

In the first Italian study2 of 1,191 patients (85% women) from 22 rheumatology centres, researchers measured levels of 25(OH)D, alongside paramaters of disease activity, calcium intake, sun exposure and bone mineral density. The association found by researchers between disease activity scores and vitamin D levels remained statistically significant when adjusted for both sun exposure and body mass index (BMI), both known risk factors for vitamin D deficiency. Significantly lower 25(OH)D levels were found in patients with active disease compared with those in disease remission (mean level 21.8 nmol/L 25(OH)D vs. 23.6 nmol/L respectively, p=0.057), and in those who were not responding to treatment compared to patients with a good response to treatment (20.5 nmol/L vs. 23.4 nmol/L p=0.020).

In the third Italian study3, 100 patients (43 with IAD and 57 with NIAD) received daily supplementation of 800-1000 IU of cholecalciferol (a form of vitamin D often used to fortify foods) over the course of six months. Abstract Numbers: FRI0509, SAT0093, SAT0506


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. DR Vitamins, LLC Introduces Vision Clarity Carnosine Eye Drops to Treat Cataracts, Glaucoma, Dry Eye, or Other Eye Ailments
2. Too Little Vitamin D May Worsen Asthma
3. Vitamin D supplements could fight Crohns disease
4. Vitamin D Linked to Survival in Lymphoma Patients
5. Low vitamin D levels associated with greater risk of relapse in childhood-onset multiple sclerosis
6. Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis
7. Vitamin Angels Responds to Haiti Disaster
8. Vitamin D May Be Tied to Heart Disease Via Genes
9. 4Rs Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance
10. VitaminSpice Elects Bill Fields to the Board of Directors
11. Shortest Day of the Year: Vitamin D - How to Get It When The Sun Goes Down
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine ... a small number of neurosurgeons in Michigan performing minimally invasive back surgery that ...
(Date:2/22/2017)... ... ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: The ... PM ET. A recording of the webinar will also be made available following its ... want to find out what really happened in the seniors housing and care merger ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, will ... on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar Convention ... our community. We are thrilled to participate in this event because we believe it ...
(Date:2/22/2017)... OAKLAND/SAN FRANCISCO BAY AREA - NORTHERN CALIFORNIA (PRWEB) , ... ... ... Forum (PMF) aims to expand the pipeline and the number of African ... support that encourages medical students and residents to pursue their careers as physicians ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... TAMPA, Fla. , Feb. 22, 2017  Corin ... Shoulder System, a device used to treat patients with ... form of shoulder arthritis. The condition, known as cuff ... arm and shoulder. The Humelock Reversed ... privately-held upper extremities technology company based near ...
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Pipeline Review, 2016" report to their offering. ... Dermatological conditions ... and approximately one-third of the US population suffers from at ... majority of the dermatology market has remained saturated with established ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By ... Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering. ... The ... growth during 2016-2022 This report provides a detailed ...
Breaking Medicine Technology: